ResMed (RMD)
(Delayed Data from NYSE)
$238.75 USD
-5.37 (-2.20%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $238.78 +0.03 (0.01%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$238.75 USD
-5.37 (-2.20%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $238.78 +0.03 (0.01%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth A Momentum A VGM
Zacks News
IDEXX (IDXX) Tops Q3 Earnings Estimates, Lowers EPS View
by Zacks Equity Research
IDEXX (IDXX) impresses investors with solid third-quarter 2019 results on robust performance across all business segments.
CONMED (CNMD) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
CONMED's (CNMD) Q3 earnings gain from higher revenues, solid segmental performance and margin expansion. However, high long-term debt remains a concern.
Merit Medical (MMSI) Q3 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Merit Medical's (MMSI) Q3 earnings gain from higher revenues and solid segmental performance benefit. However, contraction in gross margin remains a concern.
PerkinElmer (PKI) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
PerkinElmer's (PKI) Q3 earnings benefits from higher revenues and growth in DAS and Diagnostics segments. However, forex remains a woe.
ABIOMED (ABMD) Earnings Beat, Revenues Miss Estimates in Q2
by Zacks Equity Research
Impella's solid show in Japan drives ABIOMED's (ABMD) fiscal second-quarter results.
QIAGEN (QGEN) Beats Q3 Earnings Estimates, Cuts Revenue View
by Zacks Equity Research
We are impressed with QIAGEN's (QGEN) year-over-year growth across majority of operating segments in Q3.
Masimo (MASI) Earnings Beat Estimates in Q3, View Raised
by Zacks Equity Research
Masimo (MASI) raises its 2019 product revenue guidance.
Chemed (CHE) Q3 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Chemed (CHE) witnesses balanced segmental growth in third-quarter 2019.
McKesson (MCK) Q2 Earnings Meet Estimates, Revenues Beat
by Zacks Equity Research
McKesson's (MCK) Q2 results gain from higher revenues and solid show by U.S. Pharmaceutical and Specialty, and Medical-Surgical Solutions.
Fresenius Medical (FMS) Q3 Earnings & Revenues Top Estimates
by Zacks Equity Research
Fresenius Medical's (FMS) Q3 earnings benefit from strong segmental performance and solid 2019 EPS outlook.
Stryker (SYK) Q3 Earnings Meet Estimates, Revenues Beat
by Zacks Equity Research
Stryker's (SYK) Q3 earnings gain from higher revenues, solid segmental performance and strong organic growth across businesses benefit.
Cardiovascular Systems (CSII) Loss Wider Than Estimates in Q1
by Zacks Equity Research
We are upbeat about the year-over-year uptick in both Coronary and peripheral device revenues within Cardiovascular Systems' (CSII) domestic market.
Accuray (ARAY) Q1 Wider Than Expected, FY20 View Retained
by Zacks Equity Research
Accuray (ARAY) reiterates revenue and adjusted EBITDA view for fiscal 2020.
Here's Why You Should Add ResMed (RMD) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about ResMed's (RMD) performance.
Ecolab (ECL) Earnings and Revenues Miss Estimates in Q3
by Zacks Equity Research
Global Industrial unit aid Ecolab's (ECL) Q3 results; 2019 EPS view slashed.
Company News For Oct 28, 2019
by Zacks Equity Research
Companies in the news are: AMZN, BOOM, RMD, MLNT
Walgreens Boots (WBA) Q4 Earnings Surpass, Margins Fall
by Zacks Equity Research
Growth within the Retail Pharmacy USA and Pharmaceutical Wholesale divisions of Walgreens Boots (WBA) is partially offset by a dull performance at Retail Pharmacy International.
ResMed (RMD) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
ResMed (RMD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Omnicell (OMCL) Beats on Q3 Earnings, Raises '19 EPS View
by Zacks Equity Research
Omnicell (OMCL) continues to see solid segmental contributions in Q3. Expansion of gross and operating margins is a positive too.
ResMed's (RMD) Q1 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
ResMed (RMD) registers growth at CER across its key operating segments in Q1.
Cerner (CERN) Earnings Beat Estimates in Q3, Improve Y/Y
by Zacks Equity Research
Cerner (CERN) Q3 results benefit from higher revenues, gains in Licensed software, Technology resale, Professional and Managed services units, and international revenue growth.
NextGen (NXGN) Q2 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
NextGen (NXGN) retains its fiscal 2020 revenue and EPS guidance.
GNC Holdings (GNC) Q3 Loss Meets Estimates, Revenues Miss
by Zacks Equity Research
GNC Holdings' (GNC) third-quarter 2019 results, reflecting dismal performance across segments, disappoint investors.
Illumina (ILMN) Beats Q3 Earnings Estimates, Raises View
by Zacks Equity Research
Illumina (ILMN) announces impressive Q3 results on the back of strong growth in the sequencing business.
3 Reasons Growth Investors Will Love ResMed (RMD)
by Zacks Equity Research
ResMed (RMD) could produce exceptional returns because of its solid growth attributes.